INK4/ARF germline alterations in pancreatic cancer patients

被引:37
作者
Ghiorzo, P
Pastorino, L
Bonelli, L
Cusano, R
Nicora, AM
Zupo, S
Queirolo, P
Sertoli, MR
Pugliese, V
Bianchi-Scarrà, G
机构
[1] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy
[2] Ist Nazl Ric Canc, I-16132 Genoa, Italy
基金
美国国家卫生研究院;
关键词
CDKN2A; familial melanoma; G101W mutation; increased risk; p14(ARF); pancreatic cancer;
D O I
10.1093/annonc/mdg498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Roughly 40% of germinal mutations in melanoma families (MF) affect p16(INK4a) and p14(ARF). We investigated the association between INK4/ARF alterations and the occurrence of pancreatic cancer in MF and in sporadic pancreatic cancer (SPC) patients. Patients and methods: Forty-nine MF, 66 SPC cases and 54 controls were enrolled. The INK4/ARF locus was screened. Results: As compared with the general population, the risk of pancreatic cancer (PC) was increased 9.4-fold [95% confidence interval (CI) 2.7-33.4] and 2.2-fold (95% CI 0.8-5.7) in G101W-positive and -negative MF, respectively, while mean ages at onset were 61 and 77 years, respectively. A 1.7 (95% CI 1.06-2.79) increased risk of cancer at any site was observed among first-degree relatives of SPC cases as compared with controls. The G101W founder mutation was detected in 4% of SPC cases but the rate increased to 13% when tumor clustering in either branch of families was taken into account. One G101 W-positive PC patient with a melanoma in a first-degree relative harbored a germline deletion of the second allele, including exon 1B. Conclusions: The presence of a deletion including exon I B in two PC patients points to the involvement of p14(ARF) in the development of PC and may suggest that the increased risk of PC in MF is caused by impairment of both loci.
引用
收藏
页码:70 / 78
页数:9
相关论文
共 43 条
[1]  
Bahuau M, 1998, CANCER RES, V58, P2298
[2]   CDKN2A germline mutations in familial pancreatic cancer [J].
Bartsch, DK ;
Sina-Frey, M ;
Lang, S ;
Wild, A ;
Gerdes, B ;
Barth, P ;
Kress, R ;
Grützmann, R ;
Colombo-Benkmann, M ;
Ziegler, A ;
Hahn, SA ;
Rothmund, M ;
Rieder, H .
ANNALS OF SURGERY, 2002, 236 (06) :730-737
[3]   SYSTEMIC CANCER AND THE FAMMM SYNDROME [J].
BERGMAN, W ;
WATSON, P ;
DEJONG, J ;
LYNCH, HT ;
FUSARO, RM .
BRITISH JOURNAL OF CANCER, 1990, 61 (06) :932-936
[4]   High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families [J].
Borg, Å ;
Sandberg, T ;
Nilsson, K ;
Johannsson, O ;
Klinker, M ;
Måsbäck, A ;
Westerdahl, J ;
Olsson, H ;
Ingvar, C .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1260-1266
[5]  
Boyle P, 1996, INT J CANCER, V67, P63, DOI 10.1002/(SICI)1097-0215(19960703)67:1<63::AID-IJC12>3.0.CO
[6]  
2-D
[7]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[8]   The INK4a/ARF tumor suppressor: one gene - two products - two pathways [J].
Chin, L ;
Pomerantz, J ;
DePinho, RA .
TRENDS IN BIOCHEMICAL SCIENCES, 1998, 23 (08) :291-296
[9]  
Ciotti P, 1996, NEW ENGL J MED, V334, P469
[10]   A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families [J].
Ciotti, P ;
Struewing, JP ;
Mantelli, M ;
Chompret, A ;
Avril, MF ;
Santi, PL ;
Tucker, MA ;
Bianchi-Scarrà, G ;
Bressac-de Paillerets, B ;
Goldstein, AM .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (02) :311-319